Journal Article
. 2014 May; 1(1):3-7.

Challenges in the Treatment of Triple Negative and HER2-Overexpressing Breast Cancer

L Alexis Hoeferlin 1 Charles E Chalfant 1 Margaret A Park 1 
  • PMID: 24818173
  •     39 References
  •     12 citations


While the 5-year survival rate of breast cancer is at an all-time high of 90%, this disease remains the second most common cause of cancer-related death, surpassed only by lung cancer in the US. The reasons for this discrepancy stem from cancer subtypes which become resistant to current therapies. These subtypes: "Triple negative" and ErbB2-overexpressing, are discussed in this review.

Keywords: Breast Cancer; ErbB2; Estrogen receptor; Resistance; Triple negative.

Other Links

Free PMC article 
Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.
José Baselga, Patricia Gómez, +16 authors, Ahmad Awada.
J Clin Oncol, 2013 Jun 05; 31(20). PMID: 23733761    Free PMC article.
Highly Cited.
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism.
Gloria Fuentes, Maurizio Scaltriti, José Baselga, Chandra S Verma.
Breast Cancer Res, 2011 May 24; 13(3). PMID: 21600050    Free PMC article.
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Javier Cortes, Joyce O'Shaughnessy, +18 authors, EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators.
Lancet, 2011 Mar 08; 377(9769). PMID: 21376385
Highly Cited.
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Mark D Pegram, Gottfried E Konecny, +3 authors, Dennis J Slamon.
J Natl Cancer Inst, 2004 May 20; 96(10). PMID: 15150302
Highly Cited.
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.
H J Burstein, I Kuter, +12 authors, E P Winer.
J Clin Oncol, 2001 May 16; 19(10). PMID: 11352965
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.
SaeGwang Park, Zhujun Jiang, +11 authors, Yang-Xin Fu.
Cancer Cell, 2010 Aug 17; 18(2). PMID: 20708157    Free PMC article.
Highly Cited.
Recent advances in novel targeted therapies for HER2-positive breast cancer.
Conleth G Murphy, Patrick G Morris.
Anticancer Drugs, 2012 Jul 25; 23(8). PMID: 22824822
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
D J Slamon, W Godolphin, +7 authors, A Ullrich.
Science, 1989 May 12; 244(4905). PMID: 2470152
Highly Cited.
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer.
Edith A Perez, Tejal Patel, Alvaro Moreno-Aspitia.
Breast Cancer Res Treat, 2010 Mar 17; 121(2). PMID: 20229176
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, +3 authors, W L McGuire.
Science, 1987 Jan 09; 235(4785). PMID: 3798106
Highly Cited.
Updates in the treatment of basal/triple-negative breast cancer.
Mythili Shastry, Denise A Yardley.
Curr Opin Obstet Gynecol, 2012 Dec 12; 25(1). PMID: 23222093
The role of EGFR-directed therapy in the treatment of breast cancer.
Charles Morris.
Breast Cancer Res Treat, 2002 Oct 02; 75 Suppl 1. PMID: 12353824
Targeted therapy for breast cancer prevention.
Petra den Hollander, Michelle I Savage, Powel H Brown.
Front Oncol, 2013 Sep 27; 3. PMID: 24069582    Free PMC article.
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.
Brent N Rexer, Carlos L Arteaga.
Crit Rev Oncog, 2012 Apr 05; 17(1). PMID: 22471661    Free PMC article.
Highly Cited. Review.
Molecularly targeted therapies for metastatic triple-negative breast cancer.
Soley Bayraktar, Stefan Glück.
Breast Cancer Res Treat, 2013 Jan 30; 138(1). PMID: 23358903
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
Michel Marty, Francesco Cognetti, +14 authors, Jean-Marc Extra.
J Clin Oncol, 2005 May 25; 23(19). PMID: 15911866
Highly Cited.
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E Hynes, Heidi A Lane.
Nat Rev Cancer, 2005 May 03; 5(5). PMID: 15864276
Highly Cited. Review.
Therapeutic targets in triple negative breast cancer.
Sandra A O'Toole, Jane M Beith, +5 authors, Samantha R Oakes.
J Clin Pathol, 2013 Feb 26; 66(6). PMID: 23436929
Endocytosis and intracellular trafficking of ErbBs.
Alexander Sorkin, Lai Kuan Goh.
Exp Cell Res, 2009 Mar 12; 315(4). PMID: 19278030
Highly Cited. Review.
All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired.
J Baulida, M H Kraus, +2 authors, G Carpenter.
J Biol Chem, 1996 Mar 01; 271(9). PMID: 8617810
Highly Cited.
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Christoph A Ritter, Marianela Perez-Torres, +4 authors, Carlos L Arteaga.
Clin Cancer Res, 2007 Aug 19; 13(16). PMID: 17699871
Highly Cited.
Cancer statistics, 2013.
Rebecca Siegel, Deepa Naishadham, Ahmedin Jemal.
CA Cancer J Clin, 2013 Jan 22; 63(1). PMID: 23335087
Highly Cited.
Targeted therapy for breast cancer.
Ali Mohamed, Kenneth Krajewski, Burcu Cakar, Cynthia X Ma.
Am J Pathol, 2013 Aug 31; 183(4). PMID: 23988612
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.
Lisa A Carey, Hope S Rugo, +17 authors, Eric P Winer.
J Clin Oncol, 2012 Jun 06; 30(21). PMID: 22665533    Free PMC article.
Highly Cited.
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, +11 authors, Amit Oza.
Lancet Oncol, 2011 Aug 25; 12(9). PMID: 21862407
Highly Cited.
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.
José Baselga, Ian Bradbury, +25 authors, NeoALTTO Study Team.
Lancet, 2012 Jan 20; 379(9816). PMID: 22257673    Free PMC article.
Highly Cited.
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.
R Y Tsang, R S Finn.
Br J Cancer, 2012 Jan 05; 106(1). PMID: 22215104    Free PMC article.
The combination of tamoxifen and the rexinoid LG100268 prevents ER-positive and ER-negative mammary tumors in p53-null mammary gland mice.
Abhijit Mazumdar, Daniel Medina, +5 authors, Powel H Brown.
Cancer Prev Res (Phila), 2012 Aug 29; 5(10). PMID: 22926341    Free PMC article.
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
Stephen Chia, Brian Norris, +7 authors, Karen Gelmon.
J Clin Oncol, 2008 Nov 13; 26(35). PMID: 19001334
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice.
Yuxin Li, Yun Zhang, +7 authors, Powel H Brown.
Clin Cancer Res, 2007 Oct 20; 13(20). PMID: 17947490
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
Patricia M LoRusso, Denise Weiss, +2 authors, Mark X Sliwkowski.
Clin Cancer Res, 2011 Oct 18; 17(20). PMID: 22003071
Highly Cited. Review.
Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
Rachel Greenup, Adam Buchanan, +8 authors, E Shelley Hwang.
Ann Surg Oncol, 2013 Aug 27; 20(10). PMID: 23975317
Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.
Stefanos Bonovas, Kalitsa Filioussi, Nikolaos Tsavaris, Nikolaos M Sitaras.
J Clin Oncol, 2005 Nov 02; 23(34). PMID: 16260694
Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study.
Richard S Finn, Carmelo Bengala, +6 authors, Lori J Goldstein.
Clin Cancer Res, 2011 Oct 27; 17(21). PMID: 22028489
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer.
Cornelia Liedtke, Ludwig Kiesel.
Breast Care (Basel), 2011 Jul 23; 6(3). PMID: 21779231    Free PMC article.
Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.
Anette M Hommelgaard, Mads Lerdrup, Bo van Deurs.
Mol Biol Cell, 2004 Jan 27; 15(4). PMID: 14742716    Free PMC article.
Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents.
F André, C C Zielinski.
Ann Oncol, 2012 Oct 04; 23 Suppl 6. PMID: 23012302
Highly Cited. Review.
Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, +7 authors, Steven A Narod.
Clin Cancer Res, 2007 Aug 03; 13(15 Pt 1). PMID: 17671126
Highly Cited.
Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis.
Bahi Takkouche, Carlos Regueira-Méndez, Mahyar Etminan.
J Natl Cancer Inst, 2008 Oct 09; 100(20). PMID: 18840819
Welcome to the Journal of Surgery and Science!
Kazuaki Takabe.
J Surg Sci, 2014 Nov 14; 1(1). PMID: 25392848    Free PMC article.
Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifen.
Li Yin, Xiaohua Pan, +4 authors, Molin Wang.
Am J Cancer Res, 2015 May 15; 5(2). PMID: 25973295    Free PMC article.
Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.
Worapol Ngamcherdtrakul, Jingga Morry, +10 authors, Wassana Yantasee.
Adv Funct Mater, 2015 Jun 23; 25(18). PMID: 26097445    Free PMC article.
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.
Christopher Montemagno, Gilles Pagès.
Cancers (Basel), 2020 Apr 03; 12(4). PMID: 32235331    Free PMC article.
Down-regulation of tenascin-C inhibits breast cancer cells development by cell growth, migration, and adhesion impairment.
Dariusz Wawrzyniak, Małgorzata Grabowska, +4 authors, Katarzyna Rolle.
PLoS One, 2020 Aug 21; 15(8). PMID: 32817625    Free PMC article.
Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer.
Shailendra K Gautam, Ranjana K Kanchan, +13 authors, Mohd Wasim Nasser.
Cancers (Basel), 2020 Oct 07; 12(10). PMID: 33019652    Free PMC article.
Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.
Dana El-Chami, Maria Al Haddad, Ralph Abi-Habib, Mirvat El-Sibai.
Oncol Lett, 2021 Feb 09; 21(2). PMID: 33552281    Free PMC article.
Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells.
Kitti Andreidesz, Balazs Koszegi, +3 authors, Krisztina Kovacs.
Int J Mol Sci, 2021 Mar 07; 22(4). PMID: 33669671    Free PMC article.
The Role of miRNA-7 in the Biology of Cancer and Modulation of Drug Resistance.
Ewa Gajda, Małgorzata Grzanka, Marlena Godlewska, Damian Gawel.
Pharmaceuticals (Basel), 2021 Mar 07; 14(2). PMID: 33673265    Free PMC article.
Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: A systematic review and meta-analysis.
Elizabeth M Salvo, Abril Oliva Ramirez, +4 authors, Imtiaz A Samjoo.
Breast, 2021 Mar 08; 57. PMID: 33677313    Free PMC article.
Systematic Review.
Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach.
Chris Vi, Giovanni Mandarano, Sarah Shigdar.
Int J Mol Sci, 2021 Jul 03; 22(11). PMID: 34200484    Free PMC article.
TBC1D9: An Important Modulator of Tumorigenesis in Breast Cancer.
Charu Kothari, Alisson Clemenceau, +5 authors, Francine Durocher.
Cancers (Basel), 2021 Jul 25; 13(14). PMID: 34298771    Free PMC article.